KPV
Also Known As: Lys-Pro-Val, Alpha-MSH tripeptide core, MSH fragment, KPV peptide, Alpha-melanocyte-stimulating hormone C-terminal tripeptide, Anti-inflammatory tripeptide, GI anti-inflammatory peptide, MSH-derived tripeptide, KPV tripeptide, Immunomodulatory tripeptide, IBD peptide research, Mucosal healing peptide, alpha-MSH fragment
KPV is a research-grade Tripeptide C-terminal fragment of alpha-MSH targeting MC1R / melanocortin receptors studied in Healing & Recovery research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A small anti-inflammatory peptide studied mainly in gut-inflammation models.
At A Glance
| Category | Healing & Recovery |
|---|---|
| Compound Class | Tripeptide C-terminal fragment of alpha-MSH (melanocyte-stimulating hormone) |
| Molecular Target | MC1R / melanocortin receptors; NF-kB inhibition; reduces TNF-alpha, IL-1beta, IL-6 production; mucosal protection |
| Molecular Weight | 342.43 Da |
| Amino Acid Sequence | Lys-Pro-Val |
| CAS Number | 67727-97-3 |
| Half-Life | ~1.5 hours |
| WADA Status | not_listed |
| Evidence Tier | Research Compound |
Mechanism Of Action
It enters inside the cell and directly blocks a molecule (NF-kB) that acts as the main "fire alarm" for inflammation. Once blocked, the cell stops producing inflammatory chemicals.
Studied For
- GI inflammation / IBD research
- Ulcerative colitis models
- Crohn's disease models
- Skin inflammation
- Wound healing
- Immune modulation
- NF-kB pathway inhibition
- Anti-inflammatory cytokine reduction
- Mucosal barrier integrity
- Gut health restoration
- Psoriasis research
- Eczema research
- Colitis models
- Melanocortin receptor anti-inflammatory
- Systemic inflammation reduction
- Oral peptide delivery research
- anti-inflammatory
- gut healing
- Candida
- IBD
- psoriasis
- mast cell stabilization
- skin healing
- ulcerative colitis
Reported Research Findings
Cell and mouse colitis studies report reduced inflammation and mucosal healing, often using targeted nanoparticle delivery. Human efficacy is not established.
Safety And Handling Notes
Preclinical tolerability is good with low toxicity; no meaningful human adverse-event data.
No approved human indication. Research use only.
Regulatory Status
Not FDA-approved; research chemical.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.